Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
Vertex Pharmaceuticals is expanding into endocrinology with a record-breaking $10 billion acquisition of biotech specialist Crinetics.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Vertex signed an agreement to acquire Crinetics Pharmaceuticals for $10 billion. This deal, described as Vertex's largest ever, aimed to strengthen its rare disease portfolio and enter endocrinology.
Epilogue added 17d ago, after coverage quieted.
The brief
Vertex Pharmaceuticals has signed an agreement to acquire Crinetics Pharmaceuticals for $10 billion. This move allows Vertex to enter the endocrinology sector and strengthen its overall rare disease portfolio.
Coverage from Bloomberg, Fierce Pharma, and Reuters emphasizes that this is the largest deal in Vertex's history. Reports from STAT and Yahoo Finance highlight a broader boom in biotech mergers and acquisitions, noting that Crinetics' stock surged nearly 100% in after-hours trading following the announcement.
Future developments include the finalization of the takeover and the implementation of Crinetics' endocrine disease specialties into Vertex's operations. Cantor Fitzgerald has already reiterated its stock rating for Vertex in response to the deal.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 17d ago.
Quick answers
How much is Vertex paying for Crinetics?
The acquisition deal is valued at $10 billion.
What is the strategic goal of this acquisition?
Vertex aims to enter the field of endocrinology and expand its portfolio of treatments for rare diseases.
How did the market react to the news?
Crinetics stock soared nearly 100% in after-hours trading, and Cantor Fitzgerald reiterated its rating on Vertex stock.
Coverage (13)
- VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout Yahoo Finance · 20d ago
- Vertex (VRTX) Is Buying Crinetics For $10 Billion And Entering Endocrinology Yahoo Finance · 20d ago
- Vertex signs agreement to acquire Crinetics for $10bn Yahoo Finance · 20d ago
- Cantor Fitzgerald reiterates Vertex stock rating on Crinetics deal Investing.com · 20d ago
- Vertex Pharmaceuticals buying Crinetics for $10 billion qz.com · 20d ago
- Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B Fierce Pharma · 20d ago
- This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal Barron's · 20d ago
- Vertex to buy Crinetics for $10 billion in rare-diseases push Reuters · 20d ago
- Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms STAT · 20d ago
- Vertex to Buy Crinetics for $10 Billion in Biggest Deal Yet Bloomberg.com · 20d ago
- CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition Yahoo Finance · 20d ago
- Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion WSJ · 20d ago
- Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics Endpoints News · 20d ago
Topics
Related trends
Targeting Allele-Specific Faulty MRNA In SCNA2 Mutation Patients
8 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Unpacking Anthropic's 100-day sprint into biopharma: Nobel hires, M&A and major ambition
Anthropic is aggressively expanding into the biopharma sector through a 100-day sprint involving Nobel hires, M&A activity, and new research tools.
Boston Children’s and the Broad Institute partner on new center for rare genetic diseases
Three major institutions have launched the Center for Therapeutic Genetics to develop medicines for rare and ultra-rare genetic diseases.
Too Much Happiness Sent A Woman To The Emergency Room In an Incredibly Rare Case
A rare medical occurrence known as 'Happy Heart Syndrome' has led to the hospitalization of a woman following her daughter's wedding.
Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles
Vertex Pharmaceuticals is entering the endocrine disease market with a $10 billion acquisition of Crinetics.
AI helped diagnose 18 children whose rare diseases had stumped doctors
AI has successfully diagnosed 18 children with rare diseases that had previously baffled medical professionals.